SEATTLE, Aug. 22, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced the appointment of Peggy Phillips to the company's board of directors. Ms. Phillips will be replacing Richard Ulevitch, Ph.D., of 5AM Ventures, who is resigning from the board.
"We welcome Peggy to the board and look forward to benefitting from her significant experience as we continue to expand our development capabilities and grow the company," said Robert W. Overell, Ph.D., president and chief executive officer of PhaseRx. "She is an ideal addition and an accomplished biotechnology industry professional with experience in helping transform Immunex from an R&D to a commercial biopharmaceutical company. I would also like to take this opportunity to thank Richard Ulevitch for his service as a board member and for his valuable contributions to PhaseRx, both as an investor and a world-class immunologist."
Ms. Phillips served as the chief operating officer for Immunex from 1999 until 2002 when the company was acquired by Amgen. During her 16-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales, and marketing. As general manager for Enbrel®, she was responsible for clinical development, process development and regulatory affairs, as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for 10 years. She holds a B.S. and an M.S. in microbiology from the University of Idaho.
"I am particularly impressed by the mission, technology and scientific leadership of PhaseRx," said Phillips. "The company is positioned as an innovator in the field of mRNA therapeutics and I look forward to working with the PhaseRx team and its outstanding board, and to bringing its exciting future discoveries and development pipeline to the medical community."
Ms. Phillips previously served on the boards of Immunex Corporation (1996-2002), the U.S. Naval Academy Foundation (2002-2010), Western Wireless (2004-2005), Portola Pharmaceuticals (2006-2013), and Tekmira Pharmaceuticals (2014-2015). She currently serves on the board of Dynavax Technologies.
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening, inherited liver diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Head of Investor Relations
Forward Health Communications, Inc.
Robert H. Uhl
Westwicke Partners, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-appoints-peggy-phillips-to-board-of-directors-300316531.html
SOURCE PhaseRx, Inc.